Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $23.86
Previous CloseN/A
Volume4.15M
Average Volume (3M)8.35M
Market Cap
$967.77M
Enterprise ValueN/A
Total Cash (Recent Filing)$923.12M
Total Debt (Recent Filing)$230.42M
Price to Earnings (P/E)2.3
Beta1.56
Next Earnings
Aug 06, 2025EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.93
Shares Outstanding161,970,340
10 Day Avg. Volume10,129,795
30 Day Avg. Volume8,351,933
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)-1.80
Price to Sales (P/S)0.00
P/FCF Ratio-11.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$12.80Price Target Upside101.89% Upside
Rating ConsensusHold
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Product DifferentiationThe simplicity and conventional nature of Novavax's protein vaccines make them appealing to people looking for protection.
Strategic PartnershipsThe recent deal with Sanofi to distribute and co-formulate the Novavax COVID vaccines should be thought of as a blue-screen reset.
Vaccine Safety And AcceptanceThe Novavax vaccine resulted in about half as many negative symptoms compared to current mRNA vaccines, which could be advantageous in the Covid vaccination landscape.
Bears Say
Approval DelaysThe request for another randomized clinical trial for Nuvaxovid increases downside risk for potential milestones/royalties.
Financial RisksCurrent share levels are believed to overvalue the discounted forecasts of associated royalty revenue streams, leading to an underweight rating.
Regulatory ChallengesThe less favorable regulatory outlook for the COVID/Flu combo regimen is a setback and a likely impediment to meaningful business development.
---
Ownership Overview
0.40% Insiders
12.76% Mutual Funds
0.01% Other Institutional Investors
69.37% Public Companies and
Individual Investors
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $23.86 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $967.77M.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Aug 06, 2025 which is in 85 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on May 08, 2025. The company reported $2.93 earnings per share for the quarter, beating the consensus estimate of -$0.423 by $3.353.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.05.
How many shares outstanding does Novavax have?
Novavax has 161,970,340 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of $2.93 in its last earnings report, beating expectations of -$0.423. Following the earnings report the stock price went up 11.933%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
---
Novavax Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.80 (101.89% Upside)
$12.80 (101.89% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $119.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.60%
12-Months-Change
Fundamentals
Return on Equity
30.06%
Trailing 12-Months
Asset Growth
-4.47%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
---
NVAX Company Deck
---
NVAX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call reflects significant revenue growth and successful cost reduction strategies, alongside strategic partnerships and pipeline advancements. However, challenges remain with regulatory commitments and market penetration for existing products.Read More>---
NVAX Stock 12 Month Forecast
Average Price Target
$12.80
▲(101.89% Upside)
Technical Analysis
Anavex Life Sciences
―
CureVac
―
AbCellera Biologics
―
Pharvaris
―
Immunocore Holdings
―
---